Eli Lilly and Company $LLY Stock: Summit Wealth Group LLC Co. Raises Holdings

Key Points

• Summit Wealth Group increased its Eli Lilly stake by 71.2% in the third quarter, adding 1,581 shares to hold 3,803 shares valued at about $4.4 million.
• Lilly beat quarterly estimates with $24.4 billion in revenue and $7.48 EPS; revenue rose 38.6% year over year. The company also raised its 2026 revenue outlook to $91 billion–$92 billion.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus and an average price target of $1,404.14, though commentary flags valuation and the possibility of slower growth as risks.

Summit Wealth Group LLC Co. lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 71.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,803 shares of the company's stock after purchasing an additional 1,581 shares during the quarter. Summit Wealth Group LLC Co.'s holdings in Eli Lilly and Company were worth $4,400,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Integrity Financial Corp WA grew its stake in Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after buying an additional 8 shares during the last quarter. LCM Capital Management Inc increased its holdings in shares of Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company's stock worth $293,000 after buying an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV raised its stake in shares of Eli Lilly and Company by 4.1% in the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company's stock valued at $235,000 after acquiring an additional 8 shares during the last quarter. Financial Network Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company by 5.6% in the third quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company's stock valued at $175,000 after acquiring an additional 8 shares during the last quarter. Finally, Willner & Heller LLC raised its stake in shares of Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock valued at $1,100,000 after acquiring an additional 9 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Morgan Stanley increased their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Citigroup raised their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a report on Friday, October 30th. Scotiabank lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday, October 30th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,404.14.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 18,500 shares of company stock valued at $22,970,770. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 0.2%

LLY stock opened at $1,408.68 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,449.68. The company has a market cap of $1.33 trillion, a P/E ratio of 45.72, a PEG ratio of 1.77 and a beta of 0.40. The business has a fifty day moving average of $1,204.03 and a 200-day moving average of $1,095.92.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm's quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business earned $7.02 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 35.61 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 22.46%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.